

May 26, 2009
MEDRx Co. Ltd

Etodolac Patch (MRX-7EAT) became available for Phase I clinical trial in U.S.

MEDRx Co. Ltd. (a Japanese pharmaceuticals company located in Kagawa, Japan: hereinafter called MEDRx) and IL Pharma Inc. (a subsidiary of MEDRx Co., Ltd.: hereinafter called ILP) are developing Etodolac Patch (MRX-7EAT) for treatment of pain and inflammation using ILTS® (Ionic Liquid Transdermal System), our unique transdermal formulation technology. We submitted the IND (Investigational New Drug) application of MRX-7EAT to FDA (Food and Drug Administration) in U.S. on April 16th. FDA permitted the IND for Phase I trial on May 14th.

With this permission, MEDRx and ILP will start Phase I trial with healthy volunteers in early June in U.S.

MRX-7EAT is a pharmaceutical topical patch containing etodolac, one of non-steroidal anti inflammation drugs. The oral etodolac products have been widely known and used to relieve pain and inflammation. However, MRX-7EAT will be the first topical etodolac patch in the world. The results of non-clinical studies in some animals have shown the safety and efficacy of MRX-7EAT.

[FOR DETAILS, SEND E-mail at info@medrx.co.jp](mailto:info@medrx.co.jp)

< Term >

Ionic Liquid

Ionic Liquid is an ambient temperature molten salt and the melting point is lower than 100 degree Celsius. Its features are: low melting point, high ionic-conductivity, highly polarity, nonvolatility and noncombustibility. Application of Ionic Liquid in many fields including solar cells and eco-friendly reaction solvents has been considered. MEDRx is leading the world in the development of transdermal formulation drugs to make full use of its characteristics.

